{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:46:06Z","timestamp":1789213566038,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Complement inhibitors are increasingly utilized across various clinical indications, including the treatment of paroxysmal nocturnal hemoglobinuria (PNH). A thorough understanding of their adverse events (AEs) profiles, particularly regarding infections, is essential to ensure safe and effective treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To characterize the real-world AEs profile of complement inhibitors in PNH, with a focus on viral infections characteristics and distinct fatality risk, of while exploring potential implications for viral prophylaxis and identifying risk factors associated with fatal infection-related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Complement inhibitor-associated AE cases reported in FAERS between 2004 and 2024 were included. Pharmacovigilance analyses (including Reporting Odds Ratio [ROR] and multiple other metrics) were employed to detect signals for adverse events, including viral infection. Time-to-onset analysis and logistic regression were used to assess temporal patterns and identify factors associated with viral infections and fatal outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 58,613 AE reports, 11,957 (20.4%) were infection-related, and 8.91% were fatal. Infection-related AEs constituted 11,957 cases, predominantly linked to C5 inhibitors. Pharmacovigilance analysis revealed significant disproportionality signals for viral infections (e.g., influenza, herpes zoster, gastroenteritis viral, viral infection). C5 inhibitors had higher cases numbers, but C3 inhibitors demonstrated a stronger signal intensity (ROR = 3.52, 95%CI: 2.54\u20134.89). Fatal viral AEs had a median time-to-event of 12 days, while non-fatal viral infections occurred later, with a median time-to-event of 187 days. Older age, higher body weight, and treatment initiation in later quarters were associated with reduced viral infection risk, while female was linked to slightly elevated risk. While viral infections were common concomitant AEs, the fatality rate specifically for viral infections was lower compared to other complement inhibitor-associated AEs. Advanced age (\u226575 years), treatment initiation in the third quarter and C5 inhibitor use were identified as significant risk factors for fatal infectious outcomes, whereas female sex and higher body weight appeared protective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Complement inhibitors, particularly C3 agents, are associated with significant reporting of infectious AEs in FAERS, including specific viral infections like influenza and herpes. Early onset of viral AEs highlights the need for vigilance early in treatment. While advanced age and C5 use heighten mortality risk, the attenuated lethality of viral AEs suggests a distinct pathophysiological interplay warranting mechanistic study. The divergent risk profiles between C3 and C5 inhibitors underscore the need for personalized risk-benefit assessments in complement inhibition strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1639685","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:03:40Z","timestamp":1754899420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinman","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunman","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1283705","DOI":"10.3389\/fepid.2023.1283705","article-title":"Greedy knot selection algorithm for restricted cubic spline regression","volume":"3","author":"Arnes","year":"2023","journal-title":"Front. Epidemiol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/B978-0-7020-6896-6.00021-1","article-title":"21 - the human complement system: basic concepts and clinical relevance","volume-title":"Clinical immunology","author":"Atkinson","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2020.26.12-b.s3","article-title":"Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology","volume":"26","author":"Bektas","year":"2020","journal-title":"J. Manag. care & specialty Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1182\/blood-2024-203541","article-title":"Real-world adherence with pegcetacoplan in paroxysmal nocturnal hemoglobinuria compared with previously reported oral medication adherence rates","volume":"144","author":"Dingli","year":"2024","journal-title":"66th ASH Annu. Meet. Abstr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in myeloproliferative neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/s0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1212\/WNL.0000000000002312","article-title":"Eculizumab-related progressive multifocal leukoencephalopathy","volume":"86","author":"G\u00f3mez-Cibeira","year":"2016","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200730080-00001","article-title":"Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF03256199","article-title":"Review of national spontaneous reporting schemes. Strengths and weaknesses","volume":"21","author":"Hughes","year":"2002","journal-title":"Adverse drug React. Toxicol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2350814","DOI":"10.1002\/eji.202350814","article-title":"The complement system: a key player in the host response to infections","volume":"54","author":"Jayaraman","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1538563","DOI":"10.3389\/fphar.2025.1538563","article-title":"Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"143","author":"Kelly","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s12879-019-4146-5","article-title":"Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017)","volume":"19","author":"Ladhani","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","article-title":"Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database","volume":"24","author":"Le","year":"2025","journal-title":"Expert Opin. drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"108598","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin. Immunol. Orl. Fla"},{"key":"B27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","article-title":"Principles of signal detection in pharmacovigilance","volume":"16","author":"Meyboom","year":"1997","journal-title":"Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/biom12020226","article-title":"New insights into the role of the complement system in human viral diseases","volume":"12","author":"Ostrycharz","year":"2022","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0055-y","article-title":"Therapeutic targeting of the complement system","author":"Ricklin","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a target in COVID-19?","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/bcp.15791","article-title":"Improving the spontaneous reporting of suspected adverse drug reactions: an overview of systematic reviews","volume":"89","author":"Routledge","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell tissue Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.virol.2010.12.045","article-title":"Complement and viral pathogenesis","volume":"411","author":"Stoermer","year":"2011","journal-title":"Virology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s43094-025-00769-8","article-title":"Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"11","author":"Sun","year":"2025","journal-title":"Future J. Pharm. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1182\/bloodadvances.2024013587","article-title":"Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro","volume":"9","author":"Ter Avest","year":"2025","journal-title":"Blood Adv."},{"key":"B43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2165\/11592140-000000000-00000","article-title":"The case-population study design: an analysis of its application in pharmacovigilance","volume":"34","author":"Th\u00e9ophile","year":"2011","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev. MMBR"},{"key":"B45","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines advisory committee on immunization practices (ACIP)","volume":"60","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","article-title":"In the eye of the COVID-19 cytokine storm","volume":"20","author":"Vaninov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2025.2449864","article-title":"Proximal complement inhibitors in paroxysmal nocturnal hemoglobinuria: an abundance of options in a rare disease","volume":"18","author":"White","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2392885","article-title":"Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports","author":"Zhang","year":"2024","journal-title":"Expert Opin. drug Saf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1639685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:03:42Z","timestamp":1754899422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1639685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1639685"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1639685","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1639685"}}